Drug resistance in epilepsy and the ABCB1 gene: The clinical perspective

Indian Journal of Human Genetics

Volumn 17, Issue SUPPL. 1, 2011, Pages

  Das, Abhijit ^a   Balan, Shabeesh ^a,b   Banerjee, Moinak ^b   Radhakrishnan, Kurupath ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

^b RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

ABCB1; antiepileptic drugs; drug resistance; epilepsy; genetic association studies; genome wide association studies; P glycoprotein; single nucleotide polymorphism

Indexed keywords

ANTICONVULSIVE AGENT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

DNA POLYMORPHISM; EPILEPSY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PHENOTYPE; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

EID: 79956160186     PISSN: 09716866     EISSN: 1998362X     Source Type: Journal    
DOI: 10.4103/0971-6866.80353     Document Type: Review

References (67)

1. Radhakrishnan K. Challenges in the management of epilepsy in resource-poor countries. Nat Rev Neurol 2009;5:323-30.
2. Sridharan R, Murthy BN. Prevalence and pattern of epilepsy in India. Epilepsia 1999;40:631-6. (Pubitemid 29207328)
3. Radhakrishnan K, Pandian JD, Santhoshkumar T, Thomas SV, Deetha TD, Sarma PS, et al. Prevalence, knowledge, attitude, and practice of epilepsy in Kerala, South India. Epilepsia 2000;41:1027-35. (Pubitemid 30640869)
4. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9. (Pubitemid 30075244)
5. French JA. Refractory epilepsy: Clinical overview. Epilepsia 2007;48:3-7. (Pubitemid 46280512)
6. Devinsky O. Patients with refractory seizures. N Engl J Med 1999;340:1565-70. (Pubitemid 29228187)
7. Sperling MR. The consequences of uncontrolled epilepsy. CNS Spectr 2004;9:98-101, 106-9.
8. Schmidt D, Löscher W. Drug resistance in epilepsy: Putative neurobiologic and clinical mechanisms. Epilepsia 2005;46:858-77. (Pubitemid 40847354)
9. Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006;129:18-35. (Pubitemid 43063756)
10. Löscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci 2002;23:113-8. (Pubitemid 34185411)
11. Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591-602. (Pubitemid 41059334)
12. Beck H. Plasticity of antiepileptic drug targets. Epilepsia 2007;48:14-8. (Pubitemid 46280514)
13. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323:1718-22.
14. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009;50:1-23.
15. Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 2003;16:197-201. (Pubitemid 36521207)
16. Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E, et al. Limbic seizures induce P-glycoprotein in rodent brain: Functional implications for pharmacoresistance. J Neurosci 2002;22:5833-9.
17. Van Vliet EA, van Schaik R, Edelbroek PM, Voskuyl RA, Redeker S, Aronica E, et al. Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J Pharmacol Exp Ther 2007;322:141-7. (Pubitemid 46956371)
18. Marchi N, Guiso G, Rizzi M, Pirker S, Novak K, Czech T, et al. A pilot study on brain-to plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f) azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. Epilepsia 2005;46:1613-9.
19. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36:1-6.
20. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: Expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125:22-31. (Pubitemid 34084034)
21. Cucullo L, Hossain M, Rapp E, Manders T, Marchi N, Janigro D. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 2007;48:505-16. (Pubitemid 46365189)
22. Brandt C, Bethmann K, Gastens AM, Löscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 2006;24:202-11. (Pubitemid 44416217)
23. van Vliet EA, van Schaik R, Edelbroek PM, Redeker S, Aronica E, Wadman WJ, et al. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006;47:672-80.
24. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. In vivo Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity. Proc Natl Acad Sci USA 2000;97:3473-8. (Pubitemid 30183327)
25. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33. (Pubitemid 38130115)
26. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315:525-8. (Pubitemid 46175758)
27. Vahab SA, Sen S, Ravindran N, Mony S, Mathew A, Vijayan N, et al. Analysis of genotype and haplotype effects of ABCB1 (MDR1) polymorphisms in the risk of medically refractory epilepsy in an Indian population. Drug Metab Pharmacokinet 2009;24:255-60.
28. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348:1442-8. (Pubitemid 36407173)
29. Soranzo N, Cavalleri GL, Weale ME, Wood NW, Depondt C, Marguerie R, et al. Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Res 2004;14:1333-44. (Pubitemid 39029230)
30. Zimprich F, Sunder-Plassmann R, Stogmann E, Gleiss A, Dal Bianco A, Zimprich A, et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 2004;63:1087-9. (Pubitemid 39287922)
31. Hung CC, Tai JJ, Lin CJ, Lee MJ, Liou HH. Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics 2005;6:411-7. (Pubitemid 40916364)
32. Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K, et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 2006;7:551-61. (Pubitemid 43891412)
33. Kwan P, Baum L, Wong V, Ng PW, Lui CH, Sin NC, et al. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav 2007;11:112-7. (Pubitemid 47087203)
34. Ebid AH, Ahmed MM, Mohammed SA. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: A gene polymorphism perspective study. Ther Drug Monit 2007;29:305-12. (Pubitemid 47262260)
35. Hung CC, Jen TJ, Kao PJ, Lin MS, Liou HH. Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics 2007;8:1151-8.
36. Tan NC, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF, et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004;63:1090-2. (Pubitemid 39287923)
37. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 2005;46:643-7. (Pubitemid 40628658)
38. Kim YO, Kim MK, Woo YJ, Lee MC, Kim JH, Park KW, et al. Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure 2006;15:67-72. (Pubitemid 43092098)
39. Kim DW, Kim M, Lee SK, Kang R, Lee SY. Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure 2006;15:344-7. (Pubitemid 43812238)
40. Leschziner G, Jorgensen AL, Andrew T, Pirmohamed M, Williamson PR, Marson AG, et al. Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: A prospective cohort study. Lancet Neurol 2006;5:668-76. (Pubitemid 44062410)
41. Ozgon GO, Bebek N, Gul G, Cine N. Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. Eur Neurol 2007;59:67-70.
42. Shahwan A, Murphy K, Doherty C, Cavalleri GL, Muckian C, Dicker P, et al. The controversial association of ABCB1 polymorphisms in refractory epilepsy: An analysis of multiple SNPs in an Irish population. Epilepsy Res 2007;73:192-8. (Pubitemid 46331873)
43. Lakhan R, Misra UK, Kalita J, Pradhan S, Gogtay NJ, Singh MK, et al. No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. Epilepsy Behav 2009;14:78-82.
44. Grover S, Bala K, Sharma S, Gourie-Devi M, Baghel R, Kaur H, et al. Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. Biochimie 2010:92:1207-12.
45. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: A meta-analysis. Epilepsia 2009;50:898-903.
46. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273:1516-7. (Pubitemid 26301653)
47. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002;4:45-61. (Pubitemid 44698579)
48. Ioannidis JP. Genetic associations: False or true? Trends Mol Med 2003;9:135-8. (Pubitemid 36626701)
49. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: An empirical assessment. Lancet 2003;361:567-71. (Pubitemid 36207475)
50. Sisodiya S, Soranzo N, Wood NW, Goldstein DB. Association of genetic loci: Replication or not, that is the question. Neurology 2005;64:1989. (Pubitemid 40800732)
51. Berg AT, Kelly MM. Defining intractability: Comparisons among published definitions. Epilepsia 2006; 47: 431-6.
52. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069-77.
53. Sisodiya SM, Goldstein DB. Drug resistance in epilepsy: More twists in the tale. Epilepsia 2007;48:2369-70. (Pubitemid 350243407)
54. Baltes S, Fedrowitz M, Tortos CL, Potschka H, Löscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007;320:331-43. (Pubitemid 46025748)
55. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK. Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 2001;51:345-9. (Pubitemid 32391490)
56. Potschka H, Fedrowitz M, Löscher W. P-Glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001;12:3557-60. (Pubitemid 33065498)
57. Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005;76:22-76. (Pubitemid 41033402)
58. Awasthi S, Hallene KL, Fazio V, Singhal SS, Cucullo L, Awasthi YC, et al. RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci 2005;6:61.
59. Soranzo N, Kelly L, Martinian L, Burley MW, Thom M, Sali A, et al. Lack of support for a role for RLIP76 (RALBP1) in response to treatment or predisposition to epilepsy. Epilepsia 2007;48:674-83. (Pubitemid 46587613)
60. Cavalleri GL, Lynch JM, Depondt C, Burley MW, Wood NW, Sisodiya SM, et al. Failure to replicate previously reported genetic associations with sporadic temporal lobe epilepsy: Where to from here? Brain 2005;128:1832-40. (Pubitemid 41373654)
61. Lanktree MB, Dichgans M, Hegele RA. Advances in genomic analysis of stroke: What have we learned and where are we headed? Stroke 2010;41:825-32.
62. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008;322:881-8.
63. Hirschhorn JN. Genome wide Association Studies - Illuminating Biologic Pathways. N Engl J Med 2009;360:1699-701.
64. Mullen SA, Crompton DE, Carney PW, Helbig I, Berkovic SF. A neurologist's guide to genome-wide association studies. Neurology 2009;72:558-65.
65. Altshuler D, Daly M. Guilt beyond a reasonable doubt. Nat Genet 2007;39:813-5. (Pubitemid 47014482)
66. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-93. (Pubitemid 47014426)
67. Meschia JF. Stroke Genome-Wide Association Studies. The Large Numbers Imperative. Stroke 2010;41:579.